Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$0.38 - $0.53 $5,484 - $7,648
14,432 New
14,432 $5,000
Q1 2022

May 16, 2022

SELL
$0.41 - $0.7 $14,343 - $24,489
-34,985 Reduced 63.98%
19,699 $10,000
Q4 2021

Feb 14, 2022

SELL
$0.53 - $1.03 $163,834 - $318,394
-309,121 Reduced 84.97%
54,684 $31,000
Q3 2021

Nov 15, 2021

SELL
$1.0 - $1.18 $64,715 - $76,363
-64,715 Reduced 15.1%
363,805 $374,000
Q2 2021

Aug 11, 2021

SELL
$1.01 - $1.58 $302,807 - $473,698
-299,809 Reduced 41.16%
428,520 $514,000
Q1 2021

May 17, 2021

BUY
$1.23 - $5.98 $879,816 - $4.28 Million
715,298 Added 5489.2%
728,329 $947,000
Q4 2020

Feb 16, 2021

BUY
$2.09 - $5.18 $27,234 - $67,500
13,031 New
13,031 $48,000
Q3 2020

Nov 16, 2020

SELL
$1.71 - $2.68 $33,579 - $52,627
-19,637 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$1.23 - $2.12 $119,246 - $205,529
-96,948 Reduced 83.16%
19,637 $35,000
Q1 2020

May 15, 2020

BUY
$1.06 - $2.15 $79,545 - $161,342
75,043 Added 180.64%
116,585 $154,000
Q4 2019

Feb 14, 2020

BUY
$1.45 - $2.79 $17,337 - $33,360
11,957 Added 40.42%
41,542 $76,000
Q3 2019

Nov 14, 2019

BUY
$2.12 - $3.31 $18,558 - $28,975
8,754 Added 42.02%
29,585 $86,000
Q2 2019

Aug 16, 2019

BUY
$2.37 - $3.97 $1,715 - $2,874
724 Added 3.6%
20,831 $56,000
Q2 2019

Aug 14, 2019

BUY
$2.37 - $3.97 $18,398 - $30,819
7,763 Added 62.89%
20,107 $54,000
Q1 2019

May 15, 2019

BUY
$2.33 - $3.79 $5,193 - $8,447
2,229 Added 22.04%
12,344 $31,000
Q4 2018

Feb 14, 2019

SELL
$2.77 - $9.38 $16,952 - $57,405
-6,120 Reduced 37.7%
10,115 $28,000
Q3 2018

Nov 14, 2018

BUY
$5.53 - $11.36 $89,779 - $184,429
16,235 New
16,235 $145,000

Others Institutions Holding IDRA

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About IDERA PHARMACEUTICALS, INC.


  • Ticker IDRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,296,900
  • Market Cap $188M
  • Description
  • Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...
More about IDRA
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.